SGLT2 inhibitors may predispose to ketoacidosis

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 8, 2015, Pages 2849-2852

  Taylor, Simeon I ^a,b   Blau, Jenny E ^a   Rother, Kristina I ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCAGON; INSULIN; IPRAGLIFLOZIN; KETONE BODY; PHLORIZIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TOFOGLIFLOZIN; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN;

DIABETIC KETOACIDOSIS; DISEASE PREDISPOSITION; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; GLUCAGON RELEASE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KETOGENESIS; KIDNEY CLEARANCE; LIPOLYSIS; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET ALPHA CELL; PATHOGENESIS; PATIENT RISK; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; URINARY EXCRETION; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; UNITED STATES;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; DISEASE SUSCEPTIBILITY; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2; UNITED STATES;

EID: 84939142605     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-1884     Document Type: Review

References (17)

1. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587-597.
2. Food and Drug Administration. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Accessed May 25, 2015.
3. Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37:1480-1483.
4. St Hilaire R, Costello H. Prescriber beware: report of adverse effect of sodium-glucose cotransporter 2 inhibitor use in a patient with a contraindication. Am J Emerg Med. 2014;33:604.e3-604.e4.
5. JDRF. http://typeonenation.org/groups/adults/forum/topic/invokana-fort1d/. Accessed March 3, 2015.
6. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care, 2015;38:412-419.
7. The Endocrine Society. A case report of ketoacidosis associated with canagliflozin (Invokana). https://endo.confex.com/endo/2015endo/webprogram/Paper21461.html. Accessed February 14, 2015.
8. Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:65.
9. Cohen JJ, Berglund F, Lotspeich WD. Renal tubular reabsorption of acetoacetate, inorganic sulfate and inorganic phosphate in the dog as affected by glucose and phlorizin. Am J Physiol. 1956;184:91-96.
10. Martin PM, Gopal E, Ananth S, Itagaki S, Prasad BM, Ganapathy V. Identity of SMCT1 (SLC5A8) as a neuron-specific Na+-coupled transporter for active uptake of L-lactate and ketone bodies in the brain. J Neurochem. 2006;98:279-288.
11. Ruderman NB, Ross PS, Berger M, Goodman MN. Regulation of glucose and ketone-body metabolism in brain of anaesthetized rats. Biochem J. 1974;138:1-10.
12. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499-508.
13. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509-514.
14. Foster DW. Malonyl-CoA: the regulator of fatty acid synthesis and oxidation. J Clin Invest 2012;122: 1958-1959.
15. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512-517.
16. Song WJ, Mondal P, Wolfe A, et al. Glucagon regulates hepatic kisspeptin to impair insulin secretion. Cell Metab. 2014;19:667-681.
17. Yokono M, Takasu T, Hayashizaki Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol. 2014;727:66-74.